Title:
COMPOSITIONS AND METHODS FOR TREATMENT OF TYPE 1 DIABETES
Document Type and Number:
Japanese Patent JP2023166421
Kind Code:
A
Abstract:
To provide efficacious, targeted, and controlled methods and compositions for the treatment of type 1 diabetes, without causing off-target activities and systemic toxicities.SOLUTION: Compositions include lactic acid fermenting bacteria (LAB) expressing an IL-2 gene and a T1D-specific self-antigen (e.g., proinsulin (PINS)) gene. Exemplary methods include orally administering, to a mammalian subject, a therapeutically effective amount of the composition. The composition can be administered to the subject mucosally, resulting in delivery of the LAB into the gastrointestinal tract, where the LAB is released. Bioactive polypeptides expressed by the LAB are thus administered via mucosal delivery. The LAB may be selected to deliver a low-dose of IL-2 to the subject. The methods may not require concomitant systemic anti-CD3 antibody treatment. The methods may be suited for subjects possessing residual beta-cell function, e.g., those with recent-onset T1D.SELECTED DRAWING: None
Inventors:
PIETER ROTTIERS
STEIDLER LOTHAR
STEIDLER LOTHAR
Application Number:
JP2023133189A
Publication Date:
November 21, 2023
Filing Date:
August 18, 2023
Export Citation:
Assignee:
INTREXON ACTOBIOTICS NV
International Classes:
A61K35/744; A23L33/135; A61K9/02; A61K9/12; A61K9/14; A61K9/16; A61K9/20; A61K9/48; A61K35/745; A61K35/747; A61K38/20; A61K39/00; A61P3/10; C12N1/21; C12N15/12; C12N15/26
Attorney, Agent or Firm:
Hiroshi Kobayashi
Norio Omori
Emiko Nishizawa
Wataru Ueda
Norio Omori
Emiko Nishizawa
Wataru Ueda